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Introduction 
The Abbott FreeStyle Libre® flash glucose monitoring system (FGMS) is a 
novel sensor-based, factory–calibrated device that allows individuals with 
diabetes to monitor their interstitial glucose levels, capture up to 8 hours of 
interstitial glucose data, and predict future changes in interstitial glucose by 
scanning a temporary implantable glucose sensor with a reader device or 
compatible mobile phone.1 
Introduction of the device was controversial initially because of concerns 
regarding lack of evidence of clinical effectiveness. Presently there are no 
randomised controlled trials confirming the improvement in HbA1c (as a 
surrogate marker for risk of complications) seen in observational studies, 
although there is RCT evidence of significant reduction in hypoglycaemia 
for individuals with both Type 1 and Type 2 diabetes.2 The device is not 
licensed for use in pregnancy despite increasing evidence that use of 
continuous glucose monitoring systems (CGMS) is associated with a 
reduction in adverse outcomes.3 The Driver and Vehicle Licensing Agency 
have recently updated their advice that flash and continuous glucose 
monitoring systems may be used by drivers, with a requirement that 
capillary blood gluocose monitoring is required if interstitial glucose is 
4mmol/l or less.4 However, at the time of this study, the DVLA required a 
capillary blood glucose level to be measured prior to driving. 5 
NHS funding for the device became available in November 2017 in North 
Cumbria and individuals with Type 1 diabetes could be prescribed the 
device according to criteria agreed by the Regional Medicines Optimisation 
Committee (see Box 1).6 The Association of British Clinical Diabetologists 
(ABCD) are supporting nationwide data collection regarding use and impact 
of FGMS, and have produced data collection forms for central submission 
and analysis of quantitative data.7 However, the data collection forms also 
offer opportunity to collect qualitative data from individuals using the 
device in addition to health care professional comments regarding progress. 
This data provides some interesting insights into FreeStyle Libre® use and 
supports the view that FGMS has an important impact on quality of life in 
addition to (and sometimes irrespective of) quantitative clinical 
improvement measures which have been reported elsewhere for this cohort.8  
Methods 
Individuals with Type 1 diabetes who were identified as meeting RMOC 
criteria for FGMS use during the course of routine clinical care gave verbal 
consent to collection of audit data according to the recommendations of the 
ABCD Nationwide FreeStyle Libre audit, including submission to the 
central audit platform and dissemination of anonymised data locally and 
nationally.  
Data collection was undertaken as part of routine clinical care. The intention 
was to collect data using the ABCD audit form prior to FGMS initiation and 
again at 6 months. Where this was not possible, including for those users 
who had self-funded a FGMS for 6 months, the audit form for use prior to 
FGMS initiation was completed retrospectively at the same time as the 
follow up audit form, as recommended by ABCD. 
At 6 months’ follow up, additional patient comments were sought regarding 
their experience of using the FreeStyle Libre® FGMS and these were 
recorded in the relevant section on the follow up audit form. After 
completion of follow up audit forms for 40 consecutive patients, data was 
collated and analysed for local dissemination of early quantitative findings 
including overall trends towards improvement in HbA1c, hypoglycaemia 
experience and diabetes distress screening scores.8 Sixteen of the seventeen 
individuals in the cohort who had a contemporaneous DDS-2 (Diabetes 
Distress Scale-2) score available prior to use of the FreeStyle Libre® device 
and at 6 months’ follow up showed an improvement, with only 12% 
reaching a DDS-2 score >6 at follow up compared to 65% prior to 
initiation.8 A DDS-2 score of greater than 6 indicates high levels of 
“diabetes-related distress” defined as patient concerns about disease 
management, support, emotional burden and access to care, and identifies 
those who may benefit from a more detailed assessment of causes of distress 
to tailor intervention.9 Early analysis of qualitative data appeared to provide 
evidence which supported the trend toward improvement in quality of life 
scores, and this was deemed worthy of further analysis. 
Study aim and questions 
The study aim was to determine whether use of a Flash Glucose Monitoring 
System had an impact on quality of life and to explore patients’ narratives as 
to why this was the case.  
Data Collection and Analysis 
Raw data was collected as part of a brief semi-structured interview 
supported by the ABCD FreeStyle Libre® Follow-Up Visit Data Collection 
form.7  
Data was collected pragmatically at outpatient clinic follow up visits, and 
the first forty patients to complete 6 months of continuous use were 
included in the study. Participants were asked “What was positive?” and 
“What was negative?” about their experience of the device, and answers 
were transcribed by the reviewing clinician and read back to the participant 
to ensure appropriate data capture. Data were subsequently collated and 
anonymised, and because data collection had been undertaken by a single 
clinician (Consultant Diabetologist, LO), an additional researcher (Diabetes 
Specialist Dietician, ES) was recruited for data analysis to improve 
robustness and help reduce observer bias.  Thematic analysis using a 
grounded theory approach was then undertaken independently by both 
researchers ensuring that each response was considered and accounted for in 
the final analysis.10   
Feedback on use of the device was overwhelmingly (although not 
unanimously) positive.  A number of basic themes were identified 
independently by the investigators, which were then grouped into four 
organising themes: Contrast with Capillary Blood Glucose Monitoring 
(CBGM); Impact on Hypoglycaemia Experience; Glycaemic control and 
complications; and Improved Wellbeing and Quality of Life. Participant 
responses, as documented on the ABCD audit form, have been quoted to 
represent and illustrate the commonalities and variations within these 
themes. 
Findings 
Forty patients were surveyed during the course of routine review of their use 
of the device. Patients were reviewed in a number of different outpatient 
clinic settings including a general Diabetes MDT (Multidisciplinary team) 
clinic, Young Adults Clinic and Insulin Pump clinic. The age range of 
participants was 20-79 years, 46% were male, and duration of Type 1 
diabetes ranged from 4 to 56 years. Two participants were recognised to 
have cognitive impairment or learning disability and were dependent on 
additional care, and 12 participants used insulin pumps to deliver insulin 
whilst the remainder used multiple daily injections.  Seventeen of the cohort 
had initially self-funded the device. Use of the device was in accordance 
with locally agreed criteria (Box  1). 
 
Theme 1: Contrast with Capillary Blood Glucose Monitoring (CBGM) 
a) Reduction in pain and scarring associated with conventional 
CBGM 
A majority of respondents stated that no longer having to undertake 
conventional capillary blood glucose monitoring (using a lancet device to 
pierce the skin of the fingertips to measure blood glucose) was a significant 
benefit of the FGMS. The predominant complaint regarding conventional 
blood glucose monitoring was that of pain from use of the lancet device for 
conventional blood glucose monitoring. Responses included “My fingers 
are sore from blood glucose monitoring”, “I no longer have sore fingers”, 
and from the carer of an individual with cognitive impairment “His fingers 
were so sore previously”. For some users, the pain of conventional blood 
glucose monitoring was sufficient for the individual to avoid monitoring at 
detriment to their glycaemic control, for example, “when it hurts you don’t 
monitor, do you?” and “before the Libre I wouldn’t prick my fingers 
because it hurt”.     A large number of respondents identified the absence of 
“fingerpicks” as a major benefit of the FGMS, with responses including 
“taking away fingerpricks makes a big difference”, “I was sick to death of 
blood glucose monitoring”, and “fingerpricking is a chore”. 
A number of respondents identified significant scarring to their fingertips as 
a consequence of frequent testing, for example, “My fingertips were so sore 
and scarred and now they’re healing”, “I have obliterated my fingertips 
with frequent monitoring” and in one extreme case of an individual who had 
physical disability and sufficiently scarred fingertips that he could no longer 
obtain blood for conventional monitoring “I no longer have to pick at scabs 
to obtain blood for glucose testing”.  
For some individuals, conventional blood glucose monitoring had 
negatively affected their ability to work or pursue hobbies, and use of a 
FGMS had a positive impact: “It’s nice to be able to feel my fingertips - I 
couldn’t pick anything up in work”, “You need your fingers to work when 
you’re blowing up stuff for a living”, “It’s great at work when I’m doing 
cleaning jobs – more hygienic”. 
b) Alternative sites testing 
Prior to introduction of the FreeStyle Libre® FGMS device, individuals 
who had difficulty with conventional blood glucose monitoring were offered 
an alternative sites tester device to allow sampling of blood from the palm, 
forearm or even thighs if not obtainable from the fingertips. Respondents 
were generally negative about alternate sites blood glucose testing with 
responses including “alternate sites testing didn’t work”, “alternate sites 
tester was unworkable” and “alternative sites tester useless”. It is 
recognised that individuals successfully using alternate sites testers will not 
be included in this sample, but the experience of the local multi-disciplinary 
team suggests that few individuals are successfully using this alternative 
device.  
c) Use of blood testing strips and equipment 
Related to the theme of conventional blood testing is that of use of blood 
testing equipment. A number of respondents identified concerns about 
excessive consumption of blood glucose testing equipment, likely 
influenced by ongoing campaigns to reduce costs associated with capillary 
blood glucose monitoring (predominantly aimed at individuals with Type 2 
diabetes). Responses included “can scan as frequently as I like without 
worrying about fingerpricking or test strips”, “It has stopped me worrying 
about running out of test strips and equipment” and “I’m testing more 
frequently because I can” as well as numerous references to testing “more 
frequently”, “whenever I need” and “when unwell”.  
In addition, conventional blood testing equipment can be difficult for some 
users with physical disability “I can’t monitor my fingerprick glucose 
because of neuropathic pain and dexterity problems” and “I can only do 
blood glucose testing on one hand”, and these users rated the FGMS highly.    
d) Convenience and ease of use 
As predicted from the decreased reliance on painful capillary blood glucose 
monitoring, a strong theme amongst respondents was that the FGMS was 
convenient and easy to use, supporting frequent testing: “easiest thing in the 
world to check glucose regularly and frequently” and additional testing in 
situations where conventional CBGM can be more difficult, for example 
“it’s easier in work when my hands are dirty”, “I can have a quick look 
whenever I want to”, “especially good for sport”, “I can check when 
exercising, frequently”. One respondent who had used a continuous glucose 
monitoring system (CGMS) stated “It’s easier than continuous glucose 
monitoring sensors or blood glucose”.  
For individuals with learning disability, FGMS was deemed “useful for 
patients and carers”, with one individual with learning disability stating “I 
can use it on my own”. A carer for her partner with acquired cognitive 
impairment stated “I don’t have to do battle with him now to monitor his 
glucose levels”.    
Many respondents felt that the speed of using FGMs was a key 
improvement from CBGM: “The immediacy of it is brilliant”, “I can get a 
faster result or others can do it for me”, “It’s so easy and quick”, “I can 
check instantly”. 
e) Accuracy and reliability of Flash Glucose Monitoring 
The area in which most negative responses were received concerned the 
accuracy and reliability of FGM. While most users felt that the FreeStyle 
Libre® device was accurate when compared to CBGM, advising “seems to 
be as accurate as blood glucose”, “it’s really close to blood glucose 
readings”, “the sensor is pretty much the same as a blood glucose 9 times 
out of 10”, others pointed out discrepancies:  such as “the time lag and need 
to measure blood glucose”, and that the “discrepancy between blood and 
sensor glucose can be confusing”. For one respondent, this was noted but 
insufficient to prevent ongoing use of the device, given the other benefits it 
provided.  
Other users noted problems with adhesiveness of the product, including 
“difficulty getting sensors to stick. I have to wear a bandage” and “it can be 
easy to knock off”. One user noted “longest any sensor lasted was 9 days”. 
Users who noted a significant discrepancy between FGMS and CBGM 
values, or who had problems with adhesiveness of the product, were advised 
to discontinue use.  
Two users felt that it would be useful if the sensor could transmit directly to 
their insulin pump, with one user stating that “I still do blood tests to enter 
into the pump”. 
Theme 2: Impact on Hypoglycaemia Experience 
f) Improved awareness of hypoglycaemia 
Hypoglycaemia was an important theme for many respondents. A number of 
respondents with reduced awareness of hypoglycaemia, reported benefits 
from using FGMS, including subjective improvement in hypoglycaemia 
awareness, stating “my hypo awareness is better”, “pre-use I couldn’t 
detect nocturnal hypoglycaemia”. Use of the device also offered greater 
opportunity for carers to identify and intervene earlier during 
hypoglycaemia episodes: “sometimes when I’m low I rely on my wife to 
notice. Now she prompts me to check with my sensor and I treat my hypos 
more quickly” and “it allows me as a carer to help manage his diabetes and 
reduce hypos”.  Ease of use by a caregiver was seen as a positive attribute 
in this context by some “If I was hypo, someone else can use it”.  
Most users with a history of severe or frequent, disabling hypoglycaemia 
reported a reduction in frequency and severity of hypoglycaemia episodes 
and severe hypoglycaemia episodes (defined as requiring assistance of a 
third party11: “Hypos have reduced a lot – I was having several a day”, 
“fewer hypos- I’ve had none since using it”, “No severe hypos since using”, 
“I have had far fewer paramedic call outs – once 3 times in a day - and 
none since using”.  
For most respondents, reduction in hypoglycaemia was because of evasive 
action taken by the user in response to an indication from the device that 
interstitial glucose levels were declining: “able to prevent hypos by reacting 
to rapid falls”, “I’m more aware of falling glucose and able to avert 
hypoglycaemia”, “able to detect night-time hypos and change pump settings 
to avoid”.  
g) Impact of hypoglycaemia on quality of life 
A significant recurring theme was how the FGM had directly addressed the 
negative impact of frequent or disabling hypoglycaemia on quality of life 
for individuals. For example: “I no longer have the embarrassment of hypos 
in public”, “I’m no longer frightened of hypos. I used to worry because I 
live on my own and it might be four days before anyone would find me”, “I 
used to have to monitor my blood glucose through the night”.  In some 
cases, fear of hypoglycaemia was present even if the individual did not have 
frequent or severe hypoglycaemia episodes, and FGMS provided additional 
reassurance: “I no longer worry whenever I feel under the weather that it is 
due to a hypo- the sensor acts like a safeguard”, “it is a great assurance to 
family knowing that the chances of my slipping into a hypo unknowingly are 
greatly reduced”, “helps me to work out if hypo or just unwell”.   
Theme 3: Glycaemic control and complications of diabetes  
h) Improved  glycaemic control 
Reported improvement in glycaemic control was less predominant amongst 
respondents than reduction in hypoglycaemia, but a number of users 
reported tangible improvements: “I rarely have a blood glucose more than 
15”, “I’m pleased with the direction of my HbA1c”, “pleased with fall in 
HbA1c”, “my average glucose is much improved”, “lowest HbA1c in 8 
years”.  Interestingly for healthcare professionals used to reviewing CBGM 
data, one respondent stated “I can’t cheat- before you could check your 
blood glucose levels when you knew it would be OK”.  
i) Reduction in complications 
For most respondents, data collection was undertaken approximately six 
months after initiating use of a FGMS, which is not likely to be sufficiently 
long enough to detect a reduction in long term complications. Nevertheless, 
some users reported a reduction in symptoms: “neuropathy and diarrhoea 
symptoms have improved”, “my neuropathy is better”, “better quality of 
life and fewer symptoms” and there was a perception that “long term it’s 
going to stop complications”. A particularly poignant comment from an 
individual with a previous pregnancy loss was “it’s the difference between a 
normal birth…it could have prevented my previous pregnancy loss at 36 
weeks”. 
j) Trend arrows 
The FreeStyle Libre® reader device or compatible mobile phone displays 
“trend arrows” in addition to interstitial glucose levels, by using an internal 
algorithm to analyse preceding data and predict future changes in glucose 
levels. This additional feature was cited as being invaluable to patients in 
helping them to improve their diabetes control, with a large number of 
patients reporting their usefulness. The feature was referred to as “almost 
better than the values”, “a Godsend” and additional to the information 
provided by CBGM: “blood glucose is just a snapshot – the trends are 
really useful”, “the arrows help me predict and plan”. 
However, some users reported that the trend arrows could influence decision 
making more than the actual glucose values, stating “the trend arrows can 
make me overreact”, “sometimes hypo avoidance strategies because of 
downwards arrows can lead to hypers”.  
Theme 4: Improved wellbeing and quality of life 
k) Improved self-care 
A key aspect of the FGM was its role in improving patient self-care. For 
most users this reflected increased engagement with self-management, for 
example “For long term monitoring and understanding it makes it so much 
better and easier, and you pay more attention to your diabetes”, I can 
engage more with my diabetes control”, “it gives me the opportunity to 
control my blood glucose better”.  This suggested a change in behaviours 
regarding blood glucose control, such as one user who reported that prior to 
the FGM “I was really aggressively managing my diabetes and causing 
hypos”.  
The combination of ease of use, reduced time taken to measure and 
improved awareness was also reported to be of benefit to carers and partners 
of users as well: “It was great when I was unwell with migraine – my 
partner scanned me”, “my wife scans me whilst I’m driving – it’s 
reassuring”. This suggests that, in these cases, the FGM has facilitated a 
culture of self-care in the user’s lives. 
l) Confidence and empowerment 
“It’s given me reassurance and my confidence back” and “I’m in control” 
were common themes amongst users, especially those with disabling 
hypoglycaemia. Poignantly, one user reported “I can sleep at night”. For 
some users, this confidence was significant in reducing social isolation: “I 
never used to go out without my husband and recently I went to town on the 
bus on my own”, “I didn’t want to go out anymore but it’s made a lot of 
difference”.   For users with leaning or physical disability, use of the device 
represented independence: “I can manage my diabetes without the support 
of my partner”. A service user who had psychological difficulties in 
adjusting to life with diabetes since diagnosis stated “the visibility of the 
device has stopped me from hiding my diagnosis. Now the more people I 
tell, it helps me deal with it”.   
For others, the removal of the need for finger-tip testing allowed more 
lifestyle activities to be explored: “It’s nice to be able to feel my fingertips. I 
am thinking about trying to learn guitar again”. 
m) Psychological well-being and self-esteem 
Some respondents acknowledged the negative psychological impact of their 
diabetes diagnosis prior to FGMS use: “managing my diabetes used to get 
me down”, “before I had the FSL I was in a bad place, I was low, I had low 
self-esteem”. Strikingly, many users reported that using FGMS had a 
positive impact on their psychological wellbeing and self-esteem, using 
statements such as “I can’t express how much better I feel”, “Improved 
mental wellbeing”, “I feel normal. You have made me 100% better”, “I’m a 
lot happier”. Many users referred to the device as “fantastic”, “life-
changing” or a “game-changer”. Other recurring themes were “diabetes is 
less of a problem”, “makes you feel less diabetic”. 
DISCUSSION 
The themes identified in the qualitative data suggest that Flash Glucose 
Monitoring Systems can have a positive impact on most users’ quality of 
life. Four of the cohort discontinued use of the Flash Glucose Monitoring 
System, for a number of reasons including progression to insulin pump 
therapy, lack of clinical effectiveness, or problems with adhesiveness and 
unacceptable discrepancy between blood and interstital glucose levels in 
two of these users.8 Users reported improved awareness of hypoglycaemia, 
and a perception that glycaemic control had improved. Improvements in 
self-care and broader self-esteem were also linked to the use of FGMS. It is 
to be noted that users who found the device to be non-adhesive requiring 
frequent replacement of sensors, or inaccurate when compared to 
conventional capillary blood glucose monitoring, were less likely to rate the 
device as useful or report an improvement in quality of life, and were more 
likely to discontinue use. Further research is required to establish the 
disparity between readings, and the other variables which may be involved 
in this outcome. 
Alongside the strong evidence of positive impact were other significant 
findings. One such finding was in relation to hypoglycaemia, where 
participants reported a number of significant negative psychological 
sequelae associated with recurrent hypoglycaemia or fear of hypoglycaemia 
which had not previously been elicited in depth during routine clinical care. 
This indicates a potential relationship between FGM and user’s ability to 
articulate their concerns around diabetes management. Further research 
would enable the role of monitoring equipment in routine clinical care to be 
explored further. Likewise, reduction in hypoglycaemia, or reassurance that 
hypoglycaemia could be averted, appeared to have a key positive effect on 
wellbeing. This has implications for future eligibility criteria and funding of 
flash glucose systems, especially as regards those patients with reduced 
hypoglycaemia awareness. Currently, NICE recommends consideration of a 
continuous glucose monitoring system (CGMS) with hypoglycaemia alarms 
for individuals with reduced hypoglycaemia awareness.12 These systems 
have a much higher acquisition cost and are often less intuitive for users. 
However, a number of individuals reported previously unrecognised 
reduction in hypoglycaemia awareness but declined use of a CGMS system 
with alarms because of confidence in the FGMS trend arrows and 
convenience of frequent use, enabling evasive action to be taken by the user 
or their carers. Use of the device could therefore, lead to important clinical 
outcomes even for those with reduced hypoglycaemia awareness including a 
reduction in severe hypoglycaemia episodes requiring third party assistance, 
paramedic intervention and hospital admissions.  
Early local analysis of data obtained using the ABCD Nationwide FreeStyle 
Libre® Audit tools indicated that there was an improvement in quality of 
life scores for a number of patients in whom the Diabetes Distress Screening 
Scale had been recorded contemporaneously at initiation of the FreeStyle 
Libre® system. Despite the limited number of participants for whom this 
score was completed contemporaneously, this study confirms that there is a 
quality of life improvement in users of this Flash Glucose Monitoring 
system, which relates to improved awareness of glucose levels and the 
opportunity to improve glycaemic control, in terms of reducing both 
hypoglycaemic and hyperglycaemic excursions. Reducing the pain and 
other difficulties associated with conventional capillary blood glucose 
monitoring, including the stress of consuming excessive healthcare 
resources in the form of test strips and other consumables, was important to 
many users.  
CONCLUSION 
Use of a Flash Glucose Monitoring System (FGMS) by individuals with 
Type 1 diabetes selected according to agreed criteria results in an improved 
sense of wellbeing and quality of life for most users.  This relates to 
perceived improvement in glycaemic control, reduction in hypoglycaemia 
and fear of hypoglycaemia, convenience of use and enhanced feelings of 
empowerment and independence. This paper has highlighted some key 
thematic areas regarding the nature of and reasons for this impact.  
LIMITATIONS OF THE STUDY 
Due to the pragmatic nature of data collection by the Specialist Diabetes 
team, there are limitations to this study. Data collection was based on the 
ABCD audit form, and this placed some limitations on the flexibility and 
depth of data collection. Further work involving semi-structured interviews 
would enable some of the themes raised to be explored in more detail, allow 
correlation with diabetes-specific quality of life instruments, and explore the 
reasons for the themes identified in this paper in greater depth.  
It is possible that the participants are not representative of the whole 
population of individuals with Type 1 diabetes. Specifically, findings cannot 
be generalised to young people under the age of 18 years, and it is possible 
that those who did not attend for follow up had discontinued use of the 
device or found it of no benefit, leading to a positive bias amongst those 
sampled.  
  
BOX 1: RMOC Criteria for FreeStyle Libre® use in North Cumbria  
 
  
Eligible patients may be identified in Primary or Secondary Care and must have the 
following characteristics: 
 Type 1 diabetes 
 Aged 4 years and older 
 Attending Specialist Type 1 diabetes care or agreeable to referral 
 Using multiple daily injections (MDI) or CSII (insulin pump)  
 Individual or carer is willing to undertake training in use of the device 
 Agreeable to ongoing regular follow up and monitoring as deemed 
appropriate by the Diabetes Specialist team 
Individuals with these characteristics are eligible for FGMS funding if they meet one of 
the following additional criteria: 
 Undertaking intensive blood glucose monitoring 8 or more times daily 
 Those who meet the current NICE TA151 criteria for insulin pump therapy 
(HbA1c >64mmol/mol or disabling hypoglycaemia) where a successful trial of 
FreeStyle Libre® may avoid the need for pump therapy 
 Those who have recently developed impaired awareness of hypoglycaemia. 
(Please note: CGMS with an alarm function is recommended for persistent 
hypoglycaemia unawareness (NICE NG17) 
 Frequent admissions (>2 per year) with DKA or hypoglycaemia 
 Those who require third parties to carry out monitoring, and where conventional 
blood testing is not possible. 
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